PEPDar: A randomized prospective noninferiority study of ritonavir‐boosted darunavir for HIV post‐exposure prophylaxis
Authors:
Open Access
- 11 May 2016
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 17 (6) , 453-459
Abstract
Objectives: PEPDar compared the tolerability and safety of ritonavir‐boosted darunavir (DRV/r)‐based post‐exposure prophylaxis (PEP) with the tolerability and safety of standard of care (SOC). The primary endpoint was the early discontinuation rate among the per‐protocol population.Methods: PEPDar was an open‐label, randomized, multicentre, prospective, noninferiority safety study. Subjects were stratified by type of event (occupational vs. nonoccupational, i.e. sexual) and were randomized to receive DRV/r plus two nucleoside reverse transcriptase inhibitors (NRTIs) or SOC PEP. Twenty‐two private or university HIV clinics in Germany participated. Subjects were ≥ 18 years old and had documented or potential HIV exposure and indication for HIV PEP. They initiated PEP not later than 72 h after the event and were HIV negative.Results: A total of 324 subjects were screened, the per‐protocol population was 305, and 273 subjects completed the study. One hundred and fifty‐five subjects received DRV/r‐based PEP and 150 subjects received ritonavir‐boosted lopinavir (LPV/r)‐based PEP for 28–30 days; 298 subjects also received tenofovir/emtricitabine. The early discontinuation rate in the DRV/r arm was 6.5% compared with 10.0% in the SOC arm (P = 0.243). Adverse drug reactions (ADRs) were reported in 68% of DRV/r subjects and 75% of SOC subjects (P = 0.169). Fewer DRV/r subjects (16.1%) had at least one grade 2 or 3 ADR compared with SOC subjects (29.3%) (P = 0.006). All grades of diarrhoea, nausea, and sleep disorders were significantly less frequent with DRV/r, while headache was significantly more frequent. No HIV seroconversion was reported during follow‐up.Conclusions: Noninferiority of DRV/r to SOC was demonstrated. DRV/r should be included as a standard component of recommended regimens in PEP guidelines.Keywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (01KI1017, 01KG0915)
- Deutsches Zentrum für Infektionsforschung
This publication has 16 references indexed in Scilit:
- Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic ReviewClinical Infectious Diseases, 2015
- Antiretroviral Treatment of Adult HIV InfectionJAMA, 2014
- Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infectionAIDS, 2014
- Raltegravir‐emtricitabine‐tenofovir as HIV nonoccupational post‐exposure prophylaxis in men who have sex with men: safety, tolerability and adherenceHIV Medicine, 2013
- Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure ProphylaxisInfection Control & Hospital Epidemiology, 2013
- HIV seroconversion in a health care worker who underwent postexposure prophylaxis following needlestick injuryAmerican Journal of Infection Control, 2013
- Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trialHIV Medicine, 2012
- Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIVJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Seroconversion to HIV-1 Following a Needlestick Injury Despite Combination Post-exposure ProphylaxisJournal of Infection, 2001
- A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous ExposureNew England Journal of Medicine, 1997